IMI.Gel001 (#1264)
Laufzeit: 01.01.2019 - 31.12.2040
imported
Kurzfassung
Open label, randomized pilot study to evaluate safety and tolerability of a novel imiquimod formulation in the treatment of actinic keratosis (AK)
Laufzeit: 01.01.2019 - 31.12.2040
Open label, randomized pilot study to evaluate safety and tolerability of a novel imiquimod formulation in the treatment of actinic keratosis (AK)
